RSV: Consider the introduction of the monoclonal antibody against Respiratory Syncytial Virus Nirservimab to replace the monoclonal antibody Palivizumab that has been used in the country. Consider the extension of vaccination with the pneumococcal conjugate vaccine in the adult population at risk.